Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Common Equity (2019 - 2026)

Atea Pharmaceuticals' Common Equity history spans 8 years, with the latest figure at $233.7 million for Q1 2026.

  • Quarterly Common Equity fell 43.15% to $233.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $233.7 million through Mar 2026, down 43.15% year-over-year, with the annual reading at $275.4 million for FY2025, 37.24% down from the prior year.
  • Common Equity came in at $233.7 million for Q1 2026, down from $275.4 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $679.9 million in Q1 2022 to a low of $233.7 million in Q1 2026.
  • The 5-year median for Common Equity is $504.4 million (2024), against an average of $498.8 million.
  • Year-over-year, Common Equity rose 15.97% in 2022 and then crashed 43.15% in 2026.
  • Atea Pharmaceuticals' Common Equity stood at $640.6 million in 2022, then decreased by 13.33% to $555.2 million in 2023, then decreased by 20.95% to $438.9 million in 2024, then tumbled by 37.24% to $275.4 million in 2025, then dropped by 15.15% to $233.7 million in 2026.
  • Per Business Quant, the three most recent readings for AVIR's Common Equity are $233.7 million (Q1 2026), $275.4 million (Q4 2025), and $315.8 million (Q3 2025).